CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Brentuximab Vedotin|
|Indication||Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)|
|Funding Request||For the treatment of previously untreated patients with Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).|
|Pre Noc Submission||No|
|NOC Date||May 2, 2019|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||April 2, 2020|
|Submission Deemed Complete||April 21, 2020|
|Stakeholder Input Deadline ‡||April 17, 2020|
|Check-point meeting||June 3, 2020|
|pERC Meeting||September 17, 2020|
|Initial Recommendation Issued||October 1, 2020|
|Feedback Deadline ‡||October 16, 2020|
|pERC Reconsideration Meeting||November 19, 2020|
|Final Recommendation Issued||December 3, 2020|
|Notification to Implement Issued||December 18, 2020|
|Therapeutic Area||Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.